Skip to content

Oxytocin Receptor Expression in Pregnancy

Oxytocin Receptor Expression in Pregnancy: When Does it Turn on

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03907735
Enrollment
30
Registered
2019-04-09
Start date
2019-06-03
Completion date
2025-08-31
Last updated
2025-05-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemorrhage, Obstetric, Post-Abortion

Keywords

Post-abortion hemorrhage, Obstetric hemorrhage, Preterm labor, Abnormal labor, Oxytocin, Oxytocin receptor

Brief summary

This study aims to determine when during gestation oxytocin receptor (OXTR) expression increases in the myometrium, which will contribute new insight to the management of obstetric hemorrhage and our understanding of normal and abnormal labor.

Detailed description

In this descriptive study, we will obtain myometrial tissue samples by core needle biopsy under ultrasound guidance in anesthetized women immediately following surgical abortion and from controls, all of whom are undergoing a separate planned obstetric/gynecologic surgery. Tissue studies will be performed on these biopsy samples to examine oxytocin receptor expression and function.

Interventions

OTHERMyometrial tissue sample collection

Myometrial tissue samples by core needle biopsy under ultrasound guidance

Sponsors

Oregon Health and Science University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Women age 18-50 * Gestational age 14-26 weeks; or 6-13 weeks, 37-42 weeks, or non-pregnant (controls) * Undergoing another planned surgical procedure with anesthesia (suction D&C, D&E, gravid hysterectomy, cesarean section, or laparoscopic tubal ligation) * Able to give informed consent in English or Spanish

Exclusion criteria

To optimize biopsy safety, we will exclude patients with anticipated difficult cases, that have additional risks of hemorrhage, or those with features that limit ultrasound visualization. Increased risk of hemorrhage: * Anemia (Hgb \< 9) * Anticoagulation, bleeding disorder, or coagulopathy * Multiple gestation * Infection or sepsis For ultrasound-guided procedures: * Obese, BMI ≥ 40 * History of ≥2 cesarean sections * Large fibroids or uterine anomalies obstructing view * Other poor visualization * Thin myometrium \< 1cm

Design outcomes

Primary

MeasureTime frameDescription
Oxytocin receptor expression30 minutesMeasure of oxytocin receptor expression. Perform quantitative RT-PCR on mRNA extracted from biopsy samples obtained from subjects at the end of their procedure (within 30 minutes).

Secondary

MeasureTime frameDescription
Function of myometrial oxytocin receptor30 minutesAssessment of the function of the myometrial oxytocin receptor. Measure intracellular calcium in cultured myometrial cells after activating the receptor with oxytocin from biopsy samples obtained from subjects at the end of their procedure (within 30 minutes).

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026